Inomagen Therapeutics, Inc. Awarded NIH SBIR Grant Providing up to $2.9 million to Advance Disease-Modifying Gene Therapy for Atrial Fibrillation

Positive

AI Analysis

Summary

Inomagen Therapeutics received a $2.9 million NIH SBIR grant to advance preclinical development and manufacturing activities for a non-viral gene therapy targeting atrial fibrillation, with intent to support a future Investigational New Drug application.

Outcome Details

NIH SBIR Grant awarded

Importance:3/10

Sentiment:

0.60

gene therapyatrial fibrillationNIH fundingpreclinicalnon-viralSBIR grant

Related Companies

$FVNNU

Read the original article

Published by PR Newswire Biotech on September 16, 2026 2:55 PM

Read Original